FY2025 EPS Estimate for ADC Therapeutics Boosted by Analyst

Key Points

• Cantor Fitzgerald has raised its FY2025 earnings per share estimate for ADC Therapeutics to ($1.73), a notable improvement from the previous estimate of ($1.91).
• Guggenheim maintains a "buy" rating with a target price of $10.00, while Royal Bank of Canada downgraded its target price from $8.00 to $5.00, reflecting varied analyst sentiment on the stock.
• ADC Therapeutics' stock recently traded down 1.7% to $3.14, with a market capitalization of $352.69 million and a 12-month range between $1.05 and $3.97.

ADC Therapeutics SA (NYSE:ADCT - Free Report) - Investment analysts at Cantor Fitzgerald boosted their FY2025 EPS estimates for shares of ADC Therapeutics in a research note issued to investors on Wednesday, August 13th. Cantor Fitzgerald analyst E. Schmidt now expects that the company will earn ($1.73) per share for the year, up from their previous estimate of ($1.91). The consensus estimate for ADC Therapeutics' current full-year earnings is ($1.69) per share. Cantor Fitzgerald also issued estimates for ADC Therapeutics' FY2026 earnings at ($1.97) EPS.

Several other analysts have also recently issued reports on ADCT. Wall Street Zen cut ADC Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday. Guggenheim reiterated a "buy" rating and set a $10.00 target price on shares of ADC Therapeutics in a research report on Wednesday, August 13th. Finally, Royal Bank Of Canada upgraded ADC Therapeutics from an "outperform" rating to a "moderate buy" rating and cut their target price for the stock from $8.00 to $5.00 in a research report on Friday, June 20th. Four analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $7.75.

ADC Therapeutics Price Performance

Shares of NYSE:ADCT traded down $0.0050 during trading on Friday, hitting $3.1050. 497,898 shares of the company's stock were exchanged, compared to its average volume of 591,810. ADC Therapeutics has a 52-week low of $1.05 and a 52-week high of $3.97. The business's 50-day simple moving average is $3.00 and its 200 day simple moving average is $2.18. The company has a market cap of $349.31 million, a price-to-earnings ratio of -1.98 and a beta of 1.92.

ADC Therapeutics (NYSE:ADCT - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.14). The company had revenue of $18.84 million during the quarter, compared to analysts' expectations of $17.82 million.

Hedge Funds Weigh In On ADC Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Wellington Management Group LLP grew its holdings in ADC Therapeutics by 50.3% during the 4th quarter. Wellington Management Group LLP now owns 253,342 shares of the company's stock valued at $504,000 after buying an additional 84,785 shares in the last quarter. Deutsche Bank AG boosted its holdings in shares of ADC Therapeutics by 40.7% in the 4th quarter. Deutsche Bank AG now owns 56,062 shares of the company's stock worth $112,000 after purchasing an additional 16,217 shares during the period. BNP Paribas Financial Markets purchased a new position in shares of ADC Therapeutics in the 4th quarter worth approximately $1,426,000. Woodline Partners LP purchased a new position in shares of ADC Therapeutics in the 4th quarter worth approximately $3,848,000. Finally, Orbimed Advisors LLC boosted its holdings in shares of ADC Therapeutics by 31.6% in the 4th quarter. Orbimed Advisors LLC now owns 5,968,451 shares of the company's stock worth $11,877,000 after purchasing an additional 1,434,650 shares during the period. Hedge funds and other institutional investors own 41.10% of the company's stock.

About ADC Therapeutics

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.